Filing Flows › Vaxart (VXRT) › R&D spending
Vaxart (VXRT) R&D spending by quarter
Vaxart's R&D spending was $22.8M in Q3 2026 (third quarter 2026), -32% from Q2 2026. Over the last 7 quarters it ranged from $22.8M (Q3 2026) to $75.9M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $22.8M | -32% | -70% |
| Q2 2026 | $33.8M | +15% | -32% |
| Q1 2026 | $29.4M | -35% | -4% |
| Q4 2025 | $45.1M | -41% | — |
| Q3 2025 | $75.9M | +53% | — |
| Q2 2025 | $49.7M | +62% | — |
| Q1 2025 | $30.7M | — | — |
Q3 2026 at a glance
Vaxart, Q3 2026: revenue $10.6M (-85% year over year), operating margin -162.7%, net loss $17.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vaxart's R&D spending?
Vaxart's R&D spending was $22.8M in Q3 2026 (third quarter 2026), -32% from Q2 2026.
How has Vaxart's R&D spending changed?
Over the last 7 quarters it ranged from $22.8M (Q3 2026) to $75.9M (Q3 2025).